New MDMA variants could be promising alternatives for safe psychotherapeutic applications

The use of the active ingredient 3,4-methylenedioxy-N-methylamphetamine (MDMA), commonly known as "ecstasy", to support psychotherapy for mental illnesses such as post-traumatic stress disorder is being discussed worldwide. While the therapeutic potential of the substance has already been investigated in clinical trials, only Australia and New Zealand have so far decided to approve and restrict its controlled use by experts due to possible risks and side effects. An international research team led by MedUni Vienna has now identified three new variants of MDMA as promising alternatives for safer use in a controlled psychotherapeutic setting as part of a study. The results were recently published in the "Journal of Neurochemistry".

The currently developed MDMA variants (ODMA, TDMA and SeDMA) have been modified by the researchers in such a way that the positive effects are retained and the negative effects are reduced. As the studies carried out on human cell cultures by Harald Sitte's team from MedUni Vienna's Center for Physiology and Pharmacology show, the new chemical compounds have a similar effect to MDMA on the relevant clinical target structures in the brain (such as serotonin, dopamine and noradrenaline transporters), which are crucial for regulating mood and emotion. In contrast to MDMA, however, the new substances have lower activity at certain serotonin receptors and are also broken down more favorably, resulting in fewer toxic breakdown products: "This allows the conclusion that both the acute and long-term side effects of ODMA, TDMA and SeDMA may be lower than those of the conventional substance," explains study leader Harald Sitte.

Since the MDMA analogs also have a weaker interaction with certain transport proteins in the body that are responsible for the absorption and excretion of drugs, the risk of interactions with other drugs could also be reduced."

Ana Sofia Alberto-Silva, first author of the study, from MedUni Vienna's Center for Physiology and Pharmacology

Further studies needed

The psychoactive substance MDMA (3,4-methylenedioxy-N-methylamphetamine) has been known as the party drug "ecstasy" since the 1980s - although the first patent for the substance was granted back in 1912. Due to its effect of promoting positive emotions and increasing interpersonal empathy, research in recent years has focused on the potential of MDMA to support psychotherapy for various mental illnesses. However, possible risks and side effects (tachycardia, high blood pressure, liver and nerve damage) have so far been an obstacle to its widespread therapeutic use. The MDMA analogs currently identified may provide promising alternatives: "Our experimental results showed that the new variants can retain the therapeutic potential of the conventional substance, but are likely to cause fewer side effects." Harald Sitte summarizes the significance of the results: "This could advance the controlled use of psychoactive substances in neuropsychiatric illness". At the same time, the psychopharmacologist and addiction researcher emphasizes the need for further studies to comprehensively test the efficacy and safety of MDMA variants for use in a psychotherapeutic setting, for example in the treatment of post-traumatic stress disorder. 

Journal reference:

Alberto‐Silva, A. S., et al. (2024). Bioisosteric analogs of MDMA: Improving the pharmacological profile? Journal of Neurochemistry.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Active commuters less likely to suffer from heart disease and cancer, new research shows